{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T14:38:17Z","timestamp":1781534297028,"version":"3.54.5"},"reference-count":19,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"unspecified","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Batch of Science and Technology Project","award":["CJ20220086"],"award-info":[{"award-number":["CJ20220086"]}]},{"name":"Changzhou Medical Center, Nanjing Medical University","award":["CMCC202201"],"award-info":[{"award-number":["CMCC202201"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,1,27]]},"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The standard first-line treatment for driver-gene negative advanced non-small cell lung cancer (NSCLC) is chemotherapy combined with immunotherapy. However, owing to the immune microenvironment imbalance and immune status impairment caused by repeated chemotherapy, as well as the primary or secondary resistance to immune checkpoint inhibitors, the efficacy of immunotherapy combined with chemotherapy remains unsatisfactory. Recent studies have shown that faecal microbiota transplantation (FMT) can modulate the intestinal microflora, influence the tumour immune microenvironment and even enhance the efficacy of immunotherapy. Hence, we conduct such a prospective, exploratory study to evaluate the efficacy and safety of integrating FMT with standard first-line treatment in patients with driver-gene negative advanced NSCLC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>\n                      FMT-JSNO-02 (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT06403111\">NCT06403111<\/jats:ext-link>\n                      ) is a prospective, multicentre, single-arm exploratory study. It is planned to include 62 cases of previously untreated driver-gene negative, Eastern Cooperative Oncology Group Performance Status 0\u20131, programmed death ligand 1&lt;50% advanced NSCLC patients, who will be given FMT by orally ingested stool capsules on the basis of standard first-line treatment of chemotherapy combined with immunotherapy. The primary endpoint of this study is the 12-month progression-free survival rate.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The study was approved by the ethics committee of the Second People\u2019s Hospital of Changzhou (number [2024] YLJSA005) and is being conducted in accordance with the principles of the Declaration of Helsinki. The results of this study will be disseminated through publication in a peer-reviewed journal and presentation at scientific conferences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT06403111\">NCT06403111<\/jats:ext-link>\n                      . Date of registration: 7 May 2024, the first version protocol.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-094366","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T19:05:22Z","timestamp":1741115122000},"page":"e094366","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Faecal microbiota transplantation combined with platinum-based doublet chemotherapy and tislelizumab as first-line treatment for driver-gene negative advanced non-small cell lung cancer (NSCLC): study protocol for a prospective, multicentre, single-arm exploratory trial"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct06403111","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06403111","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04264975","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06403111","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06403111","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Yanshuang","family":"Wei","sequence":"first","affiliation":[{"name":"Department of Oncology, The Second People's Hospital of Changzhou, the Third Affiliated Hospital of Nanjing Medical University, Changzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanqun","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second People's Hospital of Changzhou, the Third Affiliated Hospital of Nanjing Medical University, Changzhou, China"},{"name":"Changzhou Medical Center, Nanjing Medical University, Changzhou, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second People's Hospital of Changzhou, the Third Affiliated Hospital of Nanjing Medical University, Changzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongqing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second People's Hospital of Changzhou, the Third Affiliated Hospital of Nanjing Medical University, Changzhou, China"},{"name":"Changzhou Medical Center, Nanjing Medical University, Changzhou, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danping","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second People's Hospital of Changzhou, the Third Affiliated Hospital of Nanjing Medical University, Changzhou, China"},{"name":"Changzhou Medical Center, Nanjing Medical University, Changzhou, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7871-4818","authenticated-orcid":false,"given":"Hua","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second People's Hospital of Changzhou, the Third Affiliated Hospital of Nanjing Medical University, Changzhou, China"},{"name":"Changzhou Medical Center, Nanjing Medical University, Changzhou, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2351-5042","authenticated-orcid":false,"given":"Qian","family":"Geng","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second People's Hospital of Changzhou, the Third Affiliated Hospital of Nanjing Medical University, Changzhou, China"},{"name":"Changzhou Medical Center, Nanjing Medical University, Changzhou, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,3,4]]},"reference":[{"key":"2025120618160452000_15.3.e094366.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"2025120618160452000_15.3.e094366.2","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.jtho.2021.05.005","article-title":"Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial","volume":"16","author":"Lu","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2025120618160452000_15.3.e094366.3","doi-asserted-by":"crossref","first-page":"103727","DOI":"10.1016\/j.esmoop.2024.103727","article-title":"Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: final analysis of the randomized, phase III RATIONALE-307 trial","volume":"9","author":"Wang","year":"2024","journal-title":"ESMO Open"},{"key":"2025120618160452000_15.3.e094366.4","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15497"},{"key":"2025120618160452000_15.3.e094366.5","doi-asserted-by":"publisher","DOI":"10.1146\/ANNUREV-PATHOL-042020-042741"},{"key":"2025120618160452000_15.3.e094366.6","doi-asserted-by":"crossref","first-page":"669150","DOI":"10.3389\/fimmu.2021.669150","article-title":"Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy","volume":"12","author":"Wu","year":"2021","journal-title":"Front Immunol"},{"key":"2025120618160452000_15.3.e094366.7","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad1329"},{"key":"2025120618160452000_15.3.e094366.8","doi-asserted-by":"publisher","DOI":"10.1126\/science.aac4255"},{"key":"2025120618160452000_15.3.e094366.9","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/s41577-023-00951-0","article-title":"Role of the microbiota in response to and recovery from cancer therapy","volume":"24","author":"Blake","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"2025120618160452000_15.3.e094366.10","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/d41586-022-01959-7","article-title":"How gut bacteria could boost cancer treatments","volume":"607","author":"Erdmann","year":"2022","journal-title":"Nature New Biol"},{"key":"2025120618160452000_15.3.e094366.11","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf3363"},{"key":"2025120618160452000_15.3.e094366.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2024.06.010"},{"key":"2025120618160452000_15.3.e094366.13","doi-asserted-by":"crossref","unstructured":"Li X , Zhou F , Su C . Advances in the research of mechanisms and strategies in immunotherapy resistance. Chinese Journal of Metastatic Cancer 2020;235\u201340. doi:10.1186\/s13046-021-02130-2","DOI":"10.1186\/s13046-021-02130-2"},{"key":"2025120618160452000_15.3.e094366.14","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc3421"},{"key":"2025120618160452000_15.3.e094366.15","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan3706"},{"key":"2025120618160452000_15.3.e094366.16","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan4236"},{"key":"2025120618160452000_15.3.e094366.17","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb5920"},{"key":"2025120618160452000_15.3.e094366.18","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1111\/1471-0528.15199","article-title":"Randomised controlled trials - the gold standard for effectiveness research: Study design: randomised controlled trials","volume":"125","author":"Hariton","year":"2018","journal-title":"BJOG"},{"key":"2025120618160452000_15.3.e094366.19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.149"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-094366","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T02:16:19Z","timestamp":1765073779000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-094366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":19,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,4]]},"published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1136\/bmjopen-2024-094366"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-094366","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]}}}